CA2460345A1 - 2-aroylimidazole compounds for treating cancer - Google Patents

2-aroylimidazole compounds for treating cancer Download PDF

Info

Publication number
CA2460345A1
CA2460345A1 CA002460345A CA2460345A CA2460345A1 CA 2460345 A1 CA2460345 A1 CA 2460345A1 CA 002460345 A CA002460345 A CA 002460345A CA 2460345 A CA2460345 A CA 2460345A CA 2460345 A1 CA2460345 A1 CA 2460345A1
Authority
CA
Canada
Prior art keywords
substituted
alkyl
group
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460345A
Other languages
English (en)
French (fr)
Inventor
Keizo Koya
Lijun Sun
Mitsunori Ono
David James
Weiwen Ying
Shoujun Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460345A1 publication Critical patent/CA2460345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002460345A 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer Abandoned CA2460345A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32210501P 2001-09-13 2001-09-13
US60/322,105 2001-09-13
PCT/US2002/027514 WO2003022274A2 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Publications (1)

Publication Number Publication Date
CA2460345A1 true CA2460345A1 (en) 2003-03-20

Family

ID=23253436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460345A Abandoned CA2460345A1 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Country Status (6)

Country Link
US (2) US6743919B2 (enExample)
EP (1) EP1427413A2 (enExample)
JP (1) JP2005504789A (enExample)
AU (1) AU2002323475B2 (enExample)
CA (1) CA2460345A1 (enExample)
WO (1) WO2003022274A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
JP4445266B2 (ja) * 2002-02-12 2010-04-07 ウイスコンシン アラムナイ リサーチ フオンデーシヨン Ａｈ受容体のリガンドとしてのインドールチアゾール化合物の合成
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
AU2004284420A1 (en) 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
AU2004285831B2 (en) * 2003-10-31 2011-09-15 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP5460054B2 (ja) * 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
US7960544B2 (en) * 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
US20110230464A1 (en) * 2007-10-26 2011-09-22 Paul Goldsmith Purine derivatives useful as p13 kinase inhibitors
CA2721851A1 (en) 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
US8513221B2 (en) 2008-07-07 2013-08-20 Xcovery Holding, LLC PI3K isoform selective inhibitors
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
ES2536780T3 (es) 2010-07-14 2015-05-28 F. Hoffmann-La Roche Ag Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
TW201500358A (zh) 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
EP2714680B1 (en) * 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
CN108841778B (zh) * 2018-04-28 2022-05-17 大连普瑞康生物技术有限公司 一种红豆杉细胞组织培养物
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
EP4376840A4 (en) * 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
WO2023064486A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272810A3 (en) * 1986-11-26 1988-07-20 Harbor Branch Oceanographic Institution, Inc. Antitumor and antiviral alkaloids
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5290777A (en) 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
AU727608B2 (en) * 1995-10-03 2000-12-14 Scripps Research Institute, The CBI analogs of CC-1065 and the duocarmycins
CA2268399C (en) 1996-10-31 2008-08-19 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
WO1999042092A2 (en) 1998-02-20 1999-08-26 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
ATE277010T1 (de) 1998-07-08 2004-10-15 Harbor Branch Oceanographic Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer

Also Published As

Publication number Publication date
AU2002323475B2 (en) 2006-09-28
US7081466B2 (en) 2006-07-25
JP2005504789A (ja) 2005-02-17
US6743919B2 (en) 2004-06-01
US20040186129A1 (en) 2004-09-23
WO2003022274A2 (en) 2003-03-20
WO2003022274A3 (en) 2003-07-10
EP1427413A2 (en) 2004-06-16
US20030096836A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
CA2460345A1 (en) 2-aroylimidazole compounds for treating cancer
AU2002323475A1 (en) 2-aroylimidazole compounds for treating cancer
KR101760651B1 (ko) 피롤일 치환된 다이하이드로인돌 2 온 유도체, 그의 제조 방법 및 용도
TWI870770B (zh) Parp1抑制劑及其用途
BR122023006150B1 (pt) Compostos inibidores de hpk1, seu uso, e composição farmacêutica que os compreende
AU2007218966A1 (en) 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
WO2023207556A1 (zh) Prmt5-mta抑制剂
AU2016214492A1 (en) 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
AU2002323474B2 (en) 3-glyoxlylamideindoles for treating cancer
AU2002323474A1 (en) 3-glyoxlylamideindoles for treating cancer
EP1432709B1 (en) 1-glyoxlylamide indolizines for treating cancer
CN116583501A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
CN110407854B (zh) 新的四环化合物
KR102532912B1 (ko) 자궁 내막증 치료용 인돌의 신규 유도체
JP2006505577A (ja) ３位が複素環式基によって置換されたピリドインドロン誘導体、それらの製造法およびそれらの治療用途
HK40119859A (zh) 多激酶抑制剂、其组合物及使用方法
WO2023168908A1 (zh) 稠合的醌肟咪唑及其鎓衍生物与其制备和用途
HK1079507A (en) 1-glyoxylamide indolizines for treating cancer
EP1598352A1 (en) 1-Glyoxylamide indolizines for treating cancer
HK1063322B (en) 1-glyoxylamide indolizines for treating cancer
US20100029599A1 (en) Indolylamides as modulators of the EP2 receptor

Legal Events

Date Code Title Description
FZDE Discontinued